Aurobindo Pharma Share Price: 23.1% CAGR in 3 Years as the Hyderabad Generics Major Compares With Lupin and Zydus
- November 12, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Aurobindo Pharma Share Price: 23.1% CAGR in 3 Years as the Hyderabad Generics Major Compares With Lupin and Zydus
Aurobindo Pharma previous close Rs 1,827.50. 3-year CAGR 23.1%. Up 1.9x since 10 Nov 2023. ROE 10.13%. Market cap Rs 1,05,006 crore.
Quick Answer
The Aurobindo Pharma share price closed at Rs 1,827.50 on 11 November 2026, a compounded annual return of 23.1% over three years. That compares with Lupin at 19.7% and Zydus Lifesciences at 24.6%. The company has a market cap of Rs 1,05,006 crore and a P/E of 26.34 against an industry P/E of 40.71.
The Aurobindo Pharma share price has delivered a strong return over three years, and the stock trades at a P/E well below the pharma industry level. Aurobindo Pharma, based in Hyderabad, is one of the largest generic drug makers in India and sells medicines and active ingredients in the United States, Europe and other markets.
This article compares that run with Lupin and Zydus Lifesciences. We calculate the three-year CAGR for all three and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Aurobindo Pharma Share Price Returned in 3 Years?
The Aurobindo Pharma stock closed at Rs 979.70 on 10 November 2023 and at Rs 1,827.50 on 11 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.87 lakh, which is a CAGR of 23.1%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Aurobindo Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Aurobindo Pharma share price has also followed steady demand for its generic medicines abroad, including antibiotics and treatments for chronic diseases, and the company’s large manufacturing base.
Aurobindo Pharma vs Lupin and Zydus Lifesciences: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 10 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 11 November 2026.
| Company | Close on 10 Nov 2023 | Previous close (11 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Zydus Lifesciences | Rs 619.90 | Rs 1,199.50 | 1.9x | 24.6% |
| Aurobindo Pharma | Rs 979.70 | Rs 1,827.50 | 1.9x | 23.1% |
| Lupin | Rs 1,180.15 | Rs 2,023.40 | 1.7x | 19.7% |
The Aurobindo Pharma stock ranks second of the three at 23.1%. It sits ahead of Lupin (19.7%). The company ahead is Zydus Lifesciences (24.6%). Zydus leads the group, followed by Aurobindo Pharma and then Lupin. Aurobindo Pharma sits in the middle on market cap and trades at a P/E close to Zydus.
Look at the Aurobindo Pharma share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Zydus Lifesciences | Rs 1,18,713 crore | 27.59 | 40.71 | 15.10% | 0.50 |
| Aurobindo Pharma | Rs 1,05,006 crore | 26.34 | 40.71 | 10.13% | 0.22 |
| Lupin | Rs 92,419 crore | 17.70 | 40.71 | 21.65% | 0.26 |
By market cap, Zydus Lifesciences is the largest of the group at Rs 1,18,713 crore, while the Aurobindo Pharma stock stands at Rs 1,05,006 crore, about 88% of that size. On earnings, Aurobindo Pharma shares trade at a P/E of 26.34 against an industry P/E of 40.71, a discount of about 35% to the sector, which leaves room if earnings keep growing. Peer multiples are Lupin at 17.70 and Zydus Lifesciences at 27.59.
Return on equity is 10.13% for the Aurobindo Pharma stock, which ranks third among the three, and debt to equity stands at 0.22. Trailing EPS is Rs 69.29. Generic drug makers are valued on the strength of their product pipelines, so the P/E should be read together with return on equity and the debt position.
What Is Driving the Aurobindo Pharma Stock?
Aurobindo Pharma makes oral and injectable generic medicines, active pharmaceutical ingredients and finished dosage forms. A large share of its revenue comes from the United States, with the rest from Europe, growth markets and active ingredients.
The company runs many manufacturing plants and has invested in new areas such as injectables, biosimilars and vaccines. It carries low debt, so it can fund this expansion largely from its own cash.
Followers of the Aurobindo Pharma share price usually track US generic pricing, new product approvals, performance in Europe and operating margins.
How the Established Players Stack Up
Lupin is a Mumbai-based pharma company with strength in respiratory, cardiac and anti-infective medicines and a large export business. It compounded at 19.7% a year, on a market cap of Rs 92,419 crore and an ROE of 21.65%.
Zydus Lifesciences is an Ahmedabad-based drug maker, formerly Cadila Healthcare, with generics, vaccines, biosimilars and a consumer wellness arm. It compounded at 24.6% a year, on a market cap of Rs 1,18,713 crore and an ROE of 15.10%.
What Should Investors Track Next?
Three things are worth watching on the Aurobindo Pharma share price. First, pricing and approvals in the United States. Second, progress in injectables and biosimilars. Third, margins as input costs move.
At a P/E of 26, the stock trades below the industry P/E of 41, and its debt to equity of 0.22 is low. Currency moves and US pricing can affect results, so follow quarterly numbers closely.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Aurobindo Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Aurobindo Pharma share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Aurobindo Pharma share price and compare pharma stocks live.
A Large Generic Drug Maker Priced Below the Industry Multiple
The Aurobindo Pharma share price compounded at 23.1% a year over three years, ahead of Lupin at 19.7% and behind Zydus at 24.6%. Its debt to equity of 0.22 is low and its P/E of 26.34 sits below the industry level.
Zydus brings the faster return and the largest market cap, while Lupin brings the lowest P/E and the highest ROE. The choice depends on which business mix you prefer.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Aurobindo Pharma share price today?
Ans. Aurobindo Pharma closed at Rs 1,827.50 on 11 November 2026, according to NSE data. It has a market cap of Rs 1,05,006 crore and a P/E of 26.34. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Aurobindo Pharma stock?
Ans. Aurobindo Pharma delivered a price CAGR of 23.1% over three years, moving from Rs 979.70 on 10 November 2023 to Rs 1,827.50 on 11 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Aurobindo Pharma better than Lupin?
Ans. Aurobindo Pharma delivered a higher three-year CAGR at 23.1% than Lupin at 19.7%. Aurobindo Pharma is larger by market cap at Rs 1,05,006 crore against Rs 92,419 crore, while Lupin trades at a lower P/E of 17.70 against 26.34 and has a higher ROE at 21.65% against 10.13%. The better choice depends on your view of each business.
What does Aurobindo Pharma do?
Ans. Aurobindo Pharma is a Hyderabad-based generic drug maker that sells finished medicines and active pharmaceutical ingredients in the United States, Europe and other markets.
Is the Aurobindo Pharma stock debt free?
Ans. The debt to equity ratio of the Aurobindo Pharma stock is 0.22 and its return on equity is 10.13%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Aurobindo Pharma expensive compared with the industry?
Ans. Aurobindo Pharma trades at a P/E of 26.34 against an industry P/E of 40.71. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Zydus Lifesciences delivered the highest three-year CAGR at 24.6%, followed by Aurobindo Pharma at 23.1%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.